Takeda (NYSE:TAK) recently announced that in the open-label Phase 3 SPRING study, children aged 2 to 12 had 94.8% fewer hereditary angioedema (HAE) attacks when receiving Takhzyro (lanadelumab-flyo) over 52 weeks compared to baseline
The primary objectives of the SPRING study was to evaluate the safety and pharmacokinetics of Takhzyro in HAE patients aged 2 to <12 years. The prevention of HAE attacks was a secondary outcome measure.
FDA first approved Takyzyro for heditary angiodema in 2018 for patients 12 years and older with types I and II HAE. The drug won marketing authorization throughout the European Union that same year.
To learn more about the study, we reached out to Dr. Marcus Maurer, professor of dermatology and allergy at Charité – Universitätsmedizin Berlin, Germany and principal investigator of the SPRING study.
Drug Discovery & Development (DDD): The 94.8% reduction in HAE attacks for children aged 2 to <12 seems remarkab…